title: PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.
abstract: Phosphodiesterases (PDEs) are important modulators of inflammation and wound healing. In this capacity, specific targeting of PDEs for the treatment of many diseases, including chronic obstructive pulmonary disease (COPD), has been investigated. Currently, treatment of COPD is suboptimal. PDE4 modulates the inflammatory response of the lung, and inhibition of PDE4 may be a novel, COPD-specific approach toward more effective treatment strategies. This review describes the state of PDE4-inhibitor therapy for use in COPD treatment.
authors: Section of Pulmonary, Critical Care, Sleep and Allergy, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. jmichalski@unmc.edu
authors: J M
authors: JM
authors: Michalski
authors: G
authors: G
authors: Golden
authors: J
authors: J
authors: Ikari
authors: S I
authors: SI
authors: Rennard
mesh_terms: D000818:Animals; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D058988:Phosphodiesterase 4 Inhibitors / Q000008:administration & dosage*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000201:enzymology*; D016896:Treatment Outcome
chemical_list: D058988:Phosphodiesterase 4 Inhibitors; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4